NIVESTYM
As listed in the register: NIVESTYM
300 mcg · solution
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Filgrastim
- Made by
- Pfizer Canada Ulc
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (NEUPOGEN). It describes the substance, not this exact product.
Colony-stimulating factors are glycoproteins which act on hematopoietic cells by binding to specific cell surface receptors and stimulating proliferation, differentiation commitment, and some end-cell functional activation.
Endogenous G-CSF is a lineage-specific colony-stimulating factor that is produced by monocytes, fibroblasts, and endothelial cells.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-07-23
Safety of the active substance
From the US prescribing label for the same active substance (NEUPOGEN). It describes the substance, not this exact product.
- NEUPOGEN is contraindicated in patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors such as filgrastim or pegfilgrastim [see Warnings and Precautions (5.3) ].
- Patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors such as filgrastim or pegfilgrastim.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
FranceNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Pfizer Canada Ulc |
|---|---|
| Active substance | Filgrastim |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 300 mcg |
| Form | solution |
| Classification | L03AA02 · Cancer treatments and immune-system medicines |
| Route | subcutaneous, intravenous |
| Dispensing (as stated by the register) | PRESCRIPTION · SCHEDULE D |
| Status | Marketed |
| Marketed | Yes, according to the register |
| DIN | 02485575 |
| DPD drug code | 97581 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
4 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- solution4 products
300 mcg2
300 mcg · 2 companies
- Pfizer Canada Ulc · this page
- Pfizer Canada Ulc
480 mcg2
480 mcg · 2 companies
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.